Get the Stockscreener App
1.125
1.32%
-0.015
Boundless Bio Inc stock is traded at $1.125, with a volume of 51,624.
It is down -1.32% in the last 24 hours and up +3.21% over the past month.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
See More
Previous Close:
$1.14
Open:
$1.1593
24h Volume:
51,624
Relative Volume:
0.39
Market Cap:
$25.18M
Revenue:
-
Net Income/Loss:
$-64.39M
P/E Ratio:
-0.3896
EPS:
-2.8877
Net Cash Flow:
$-56.24M
1W Performance:
-3.02%
1M Performance:
+3.21%
6M Performance:
-2.17%
1Y Performance:
-33.82%
1-Day Range:
$1.12
$1.1599
1-Week Range:
$1.12
$1.18
52-Week Range:
$0.9612
$1.80
Boundless Bio Inc Stock (BOLD) Company Profile
Name
Boundless Bio Inc
Sector
Industry
Phone
(858) 766-9912
Address
10955 ALEXANDRIA WAY, SAN DIEGO
Compare BOLD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BOLD
Boundless Bio Inc
|
1.125 | 25.52M | 0 | -64.39M | -56.24M | -2.8877 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.31 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
763.61 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
722.13 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.36 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.37 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Boundless Bio Inc Stock (BOLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Initiated | H.C. Wainwright | Buy |
| May-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-13-24 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-22-24 | Initiated | Guggenheim | Buy |
| Apr-22-24 | Initiated | Leerink Partners | Outperform |
| Apr-22-24 | Initiated | Piper Sandler | Overweight |
View All
Boundless Bio Inc Stock (BOLD) Latest News
Boundless Bio to Participate in the Leerink Global Healthcare Conference - The Manila Times
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight – Company AnnouncementFT.com - Financial Times
BOLD Should I Buy - Intellectia AI
BOLD SEC FilingsBOUNDLESS BIO INC 10-K, 10-Q, 8-K Forms - Stock Titan
MDCX PE Ratio & Valuation, Is MDCX Overvalued - Intellectia AI
Signal Recap: How liquid is AMBIWS stock2025 Retail Activity & AI Enhanced Trading Alerts - baoquankhu1.vn
Volume Recap: Can Broadstone Net Lease Inc outperform under higher oil prices2025 Geopolitical Influence & Weekly Setup with High ROI Potential - baoquankhu1.vn
Nextech exits Boundless Bio (NASDAQ: BOLD) with reported 0% ownership - Stock Titan
Will Boundless Bio Inc. stock continue dividend increasesInflation Watch & Consistent Income Trade Recommendations - mfd.ru
What Makes CTS (CTS) a New Buy Stock - Bitget
What Makes KB Financial (KB) a Strong Momentum Stock: Buy Now? - Bitget
Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's Why - Yahoo Finance
Boundless Bio Advances New Breast Cancer Drug BBI-940 Into First-in-Human Trial - TipRanks
FMR LLC Reduces Stake in Boundless Bio Inc: A Strategic Portfoli - GuruFocus
What is the long term forecast for Boundless Bio Inc. stockJuly 2025 Analyst Calls & Weekly High Conviction Ideas - mfd.ru
Investment Recap: What are the analyst revisions for Boundless Bio IncIs RAAQU stock a good investment in YEARJuly 2025 Chart Watch & Fast Exit Strategy with Risk Control - baoquankhu1.vn
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Fed Watch: Does Boundless Bio Inc have pricing powerWall Street Watch & Momentum Based Trading Signals - baoquankhu1.vn
Finance Watch: Four IPOs In One Week - Citeline News & Insights
Fund Flows: Can Boundless Bio Inc weather a recession2025 Investor Takeaways & AI Forecast Swing Trade Picks - baoquankhu1.vn
Boundless Bio CEO Zachary Hornby to Speak at Guggenheim Emerging Outlook: Biotech Summit 2026 - Quiver Quantitative
Cancer biotech Boundless Bio preps Guggenheim fireside chat with online webcast - Stock Titan
Is Boundless Bio (NASDAQ:BOLD) In A Good Position To Invest In Growth? - simplywall.st
Patterns Watch: Is Boundless Bio Inc subject to activist investor interestQuarterly Trade Review & Risk Managed Investment Strategies - baoquankhu1.vn
We're Keeping An Eye On Boundless Bio's (NASDAQ:BOLD) Cash Burn Rate - Yahoo Finance
Layoff Tracker: Gilead Continues California Cuts With 34 Laid Off - BioSpace
Is Boundless Bio Inc. stock a good pick for beginnersJuly 2025 Short Interest & AI Driven Price Predictions - mfd.ru
Boundless Bio (BOLD) awards 140,000-share stock option to finance chief - Stock Titan
Day Trade: How does HSIC compare to its peers2025 Key Lessons & Capital Efficiency Focused Ideas - baoquankhu1.vn
Update Report: Is Alamos Gold Inc forming bullish engulfing patterns2025 Price Momentum & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Short Squeeze: Is Toppoint Holdings Inc a speculative investmentJuly 2025 WrapUp & Consistent Profit Trade Alerts - baoquankhu1.vn
Aug Drivers: Can MBNKP continue delivering strong returnsWeekly Trade Analysis & Smart Investment Allocation Insights - baoquankhu1.vn
VIX Spike: Is PHVS forming a bullish divergenceJuly 2025 Weekly Recap & Technical Pattern Based Signals - baoquankhu1.vn
Boundless Bio’s kinesin degrader gains IND approval - BioWorld MedTech
FDA accepts Boundless Bio’s IND for novel cancer drug BBI-940 - Investing.com Canada
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 And Extends Cash Runway - TradingView
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway - marketscreener.com
Boundless Bio halts trial to back new breast cancer drug to 2028 - Stock Titan
Can Boundless Bio Inc. stock withstand economic slowdownMarket Activity Recap & AI Driven Price Predictions - bollywoodhelpline.com
What is POLA’s market positionRecession Risk & Daily Technical Forecast Reports - bollywoodhelpline.com
Trump's Policies Stir Crypto Market Uncertainty - Intellectia AI
Earnings Report: Will ACRPRC stock go up in YEAR2025 Dividend Review & AI Driven Stock Price Forecasts - baoquankhu1.vn
How First Trust EIP Power Solutions stock reacts to monetary easingQuarterly Trade Summary & Low Risk Investment Opportunities - Bollywood Helpline
Sentiment Watch: Does G III Apparel Group Ltd stock benefit from AI growthMarket Growth Summary & Reliable Entry Point Alerts - baoquankhu1.vn
Winners Losers: Is ZNTL forming a bullish divergence2025 Market Sentiment & Growth-Oriented Investment Plans - baoquankhu1.vn
Sectors Review: Whats the fair value of POWPRB stockJuly 2025 Sector Moves & Low Risk High Win Rate Picks - baoquankhu1.vn
Boundless Bio Terminates Early-Stage BBI-825 Cancer Trial: What Investors Should Know - TipRanks
Can R M Drip and Sprinklers Systems Limited Regain Momentum After Breakdown2025 Year in Review & Safe Capital Growth Plans - Bollywood Helpline
Chart Watch: Is Boundless Bio Inc stock a defensive play in 2025Weekly Loss Report & Stock Portfolio Risk Management - Bộ Nội Vụ
How rising interest rates impact Boundless Bio Inc. stockMarket Activity Summary & Low Drawdown Investment Strategies - ulpravda.ru
Why Boundless Bio Inc. stock remains resilientJuly 2025 Spike Watch & Weekly Watchlist of Top Performers - ulpravda.ru
Boundless Bio Inc Stock (BOLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.07%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):